New Data Reported From Trials of Drug Developed at Yale Pathology to Treat Rare, Often Fatal Neonatal Disorder
Clinical trial data from an enzyme-therapy drug developed at Yale Pathology to treat a rare and often fatal neonatal calcification disorder were recently reported. The drug, INZ-701, was designed and validated in the laboratory of Demetrios Braddock, MD, PhD, Associate Professor of Pathology at Yale School of Medicine.
Researchers Identify Stem Cell Source of Key Process in Female Reproduction
Each month during women’s reproductive years, the uterus sheds and regenerates the tissue lining its walls in preparation for a pregnancy or the next cycle. The process behind this age-old and essential part of human reproduction is not well understood. But recent research led by Yale pathologist Wang Min identifies stem cells and a gene that contribute to this monthly event.
Study explores new strategy to develop a malaria vaccine
A serum developed by Yale researchers reduces infection from malaria in mice, according to a new study. It works by attacking a protein in the saliva of the mosquitos infected with the malaria parasite rather than the parasite itself. If the novel approach proves effective in further studies, it could potentially be used to enhance existing malaria vaccines, the researchers said.
Researchers develop a novel RNA-based therapy to target West Nile Virus
A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The enemy within: Gut bacteria drive autoimmune disease
Bacteria found in the small intestines of mice and humans can travel to other organs and trigger an autoimmune response, according to a new Yale study. The researchers also found that the autoimmune reaction can be suppressed with an antibiotic or vaccine designed to target the bacteria, they said.
New test shows when body is fighting a virus
A new test that measures RNA or protein molecules in human cells can accurately identify viral infection as a cause of respiratory symptoms, according to a Yale study published Dec. 21 in The Journal of Infectious Diseases. Performed with a simple nasal swab, the test could prove to be a quicker, cheaper way to diagnose respiratory viral illnesses than current methods, the researchers said.
Yale doctor creates new weapons to kill cancer
The battle against cancer is increasingly being fought on the genetic level, and Dr. Samuel Katz is aiding the body’s immune system by creating safer, more effective weapons. His research is focused on treating cancers of the blood, such as multiple myeloma, Hodgkin’s lymphoma and acute myeloid leukemia, but his technique could eventually be used against solid tumors as well, including cancers of the breast, ovary, pancreas and colon. Most gene therapy uses genetically modified DNA in the body’s T lymphocytes — a type of white blood cell that is an integral part of the body’s immune system — to find, attack and kill cancer cells.Source: New Haven Register
Zika-related nerve damage caused by immune response to the virus
The immune system’s response to the Zika virus, rather than the virus itself, may be responsible for nerve-related complications of infection, according to a Yale study. This insight could lead to new ways of treating patients with Zika-related complications, such as Guillain-Barré syndrome, the researchers said.
Promising Yale cancer research supported by Stamford based non-profit leading charge in gene therapy studies
Support from ACGT has Dr. Samuel Katz at Yale School of Medicine refining the current research. He is reprogramming cells, with RNA, the genetic material that delivers the message, to destroy the cancerous ones — acting as soldiers in battle, if you will. “We give them the message,” says Dr. Katz, “and then the message goes away, and when the soldier is done with his job he returns back to normal.” If successful, this approach will make safer and stronger cells – a super-soldier that reintegrates into society when the war is won.Source: WTNH News Channel 8
Study uncovers markers for severe form of multiple sclerosis
Scientists have uncovered two closely related cytokines — molecules involved in cell communication and movement — that may explain why some people develop progressive multiple sclerosis (MS), the most severe form of the disease. The findings, authored by researchers at Yale University, Oregon Health & Science University, and the University of California point the way toward developing a novel treatment to prevent progressive forms of the disease.
Limiting lung cancer’s spread and growth in the brain
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers. In many patients diagnosed with LUAD, tumors cells have already spread to the brain, leading to decreased quality of life and low survival rates. A Yale Cancer Center research team conducted a study to determine how those tumor cells manage to grow outside the lungs.
Researchers at Yale have taken steps toward a ‘completely unexpected’ new way to treat brain cancer
Researchers at Yale think they've come up with a new way to treat a certain kind of brain tumor using a drug that's already been approved by the FDA. In a study published Wednesday in the journal Science Translational Medicine, the researchers outline a hypothesis for using the drug to tackle brain cancer. Thing is, the hypothesis they put forward is the exact opposite of the one other scientists, as well as several drug companies including Agios Pharmaceuticals, had previously been working with. The drug they discuss, called a PARP inhibitor, blocks a protein our cells use to repair DNA and kill off tumors. In certain kinds of cancer, that repair system is broken, which allows cancer cells to thrive.Source: Yahoo Finance
The promise of precision medicine for rheumatoid arthritis
In a new study, a Yale-led research team identified the mechanism of a gene that raises the risk of severe rheumatoid arthritis in susceptible individuals. The finding may lead to the development of treatment based on the genetic profiles of arthritis patients, the researchers said.